89bio shares maintain Buy rating as analyst cites confidence in pegozafermin trial outcomes
H.C. Wainwright reiterated its Buy rating and $29.00 price target for 89bio Inc . (NASDAQ:ETNB) shares. According to InvestingPro data, the stock currently trades at $6.31, near its 52-week low of $5.
89bio’s Promising Drug Developments and Stable Financial Outlook Justify Buy Rating
(ETNB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C.
89bio’s (ETNB) “Sell (D-)” Rating Reiterated at Weiss Ratings
Weiss Ratings reiterated their sell (d-) rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research note released on Saturday,Weiss Ratings reports. A number of other research analysts also ...
89bio (NASDAQ:ETNB) Sets New 1-Year Low Following Insider Selling
Inc. (NASDAQ:ETNB – Get Free Report)’s share price hit a new 52-week low during trading on Friday following insider selling activity. The stock traded as low as $5.99 and last traded at $6.09, with a ...
89bio's chief technical operations officer sells $71,149 in stock
Nguyen Quoc, the Chief Technical Operations Officer at 89bio, Inc. (NASDAQ:ETNB), has sold shares worth approximately $71,149, according to a recent SEC filing. The transaction comes as the stock ...